• 목록
• 답변
• 글쓰기
• 게시판 리스트 옵션
  • 수정
  • 삭제

Personalized Depression Treatment

Traditional treatment and medications don't work for a majority of people who are depressed. A customized treatment may be the answer.

Cue is an intervention platform for digital devices that transforms passively acquired smartphone sensor data into personalized micro-interventions designed to improve mental health. We analysed the best-fit personalized ML models for each subject using Shapley values to identify their predictors of feature and reveal distinct characteristics that can be used to predict changes in mood with time.

Predictors of Mood

Depression is a leading cause of mental illness in the world.1 Yet the majority of people suffering from the condition receive treatment. To improve outcomes, clinicians must be able to identify and treat patients most likely to benefit from certain treatments.

The ability to tailor Depression Treatment London treatments is one method of doing this. Researchers at the University of Illinois Chicago are developing new methods to predict which patients will benefit most from specific treatments. They use sensors on mobile phones as well as a voice assistant that incorporates artificial intelligence and other digital tools. Two grants totaling more than $10 million will be used to identify biological and behavioral indicators of response.

The majority of research done to so far has focused on sociodemographic and clinical characteristics. These include demographics such as gender, age, and education, and clinical characteristics such as symptom severity and comorbidities, as well as biological markers.

While many of these variables can be predicted from information in medical records, only a few studies have used longitudinal data to explore predictors of mood in individuals. A few studies also consider the fact that mood can be very different between individuals. Therefore, it is essential to develop methods that permit the determination of the individual differences in mood predictors and treatment effects.

The team's new approach uses daily, in-person evaluations of mood and lifestyle variables using a smartphone app called AWARE, a cognitive evaluation with the BiAffect app and electroencephalography -- an imaging technique that monitors brain activity. The team can then develop algorithms to identify patterns of behaviour and emotions that are unique to each individual.

The team also created a machine-learning algorithm that can identify dynamic predictors of the mood of each person's depression. The algorithm integrates the individual differences to produce an individual "digital genotype" for each participant.

This digital phenotype was associated with CAT DI scores, a psychometrically validated symptom severity scale. The correlation was not strong however (Pearson r = 0,08, P-value adjusted for BH = 3.55 10 03) and varied greatly between individuals.

Predictors of symptoms

Depression is a leading reason for disability across the world, but it is often misdiagnosed and untreated2. Depression disorders are rarely treated due to the stigma associated with them and the absence of effective interventions.

To aid in the development of a personalized treatment, it is important to determine the predictors of symptoms. However, the current methods for predicting symptoms are based on the clinical interview, which is unreliable and only detects a small number of symptoms that are associated with depression.2

Machine learning can increase the accuracy of diagnosis and treatment for depression by combining continuous digital behavior phenotypes collected from smartphone sensors with a validated mental health tracker online (the Computerized Adaptive Testing Depression Inventory CAT-DI). These digital phenotypes are able to capture a variety of unique behaviors and activities that are difficult to capture through interviews, and allow for continuous and high-resolution measurements.

The study included University of California Los Angeles (UCLA) students experiencing moderate to severe depressive symptoms. enrolled in the Screening and electric treatment for depression for Anxiety and Depression (STAND) program29 that was created under the UCLA Depression Grand Challenge. Participants were directed to online assistance or in-person clinics depending on their depression severity. Participants with a CAT-DI score of 35 or 65 were assigned online support by a coach and those with a score 75 patients were referred for psychotherapy in person.

At the beginning of the interview, participants were asked a series of questions about their personal demographics and psychosocial characteristics. These included sex, age, education, work, and financial status; whether they were divorced, married or single; the frequency of suicidal ideas, intent or attempts; as well as the frequency with that they consumed alcohol. The CAT-DI was used for assessing the severity of depression symptoms on a scale ranging from 0-100. The CAT-DI test was conducted every two weeks for participants who received online support, and weekly for those who received in-person assistance.

Predictors of the Reaction to Treatment

Research is focused on individualized depression treatment. Many studies are aimed at identifying predictors, which will help doctors determine the most effective drugs to treat each individual. Particularly, pharmacogenetics is able to identify genetic variants that influence how the body's metabolism reacts to antidepressants. This allows doctors to select the medications that are most likely to work best for each patient, while minimizing the time and effort required in trial-and-error treatments and avoid any adverse effects that could otherwise hinder progress.

Another promising method is to construct models for prediction using multiple data sources, such as the clinical information with neural imaging data. These models can then be used to determine the most appropriate combination of variables predictors of a specific outcome, such as whether or not a medication is likely to improve the mood and symptoms. These models can be used to predict the response of a patient to treatment, allowing doctors maximize the effectiveness.

A new generation of studies utilizes machine learning techniques like supervised learning and classification algorithms (like regularized logistic regression or tree-based methods) to combine the effects of many variables and increase predictive accuracy. These models have been shown to be useful in predicting the outcome of treatment, such as response to antidepressants. These approaches are becoming more popular in psychiatry and could be the norm in future medical practice.

Research into depression treatment effectiveness's underlying mechanisms continues, as well as predictive models based on ML. Recent research suggests that the disorder is connected with neural dysfunctions that affect specific circuits. This suggests that an individualized treatment for depression will be based on targeted treatments that restore normal function to these circuits.

Internet-delivered interventions can be an effective method to accomplish this. They can offer more customized and personalized experience for patients. One study found that a program on the internet was more effective than standard treatment in alleviating symptoms and ensuring a better quality of life for those with MDD. In addition, a controlled randomized study of a personalised approach to depression treatment showed sustained improvement and reduced adverse effects in a significant percentage of participants.

Predictors of adverse effects

A major issue in personalizing depression treatment is predicting which antidepressant medications will cause the least amount of side effects or none at all. Many patients are prescribed a variety of medications before settling on a treatment that is effective and tolerated. Pharmacogenetics provides an exciting new method for an effective and precise approach to choosing antidepressant medications.

There are several predictors that can be used to determine the antidepressant to be prescribed, including gene variations, patient phenotypes like gender or ethnicity, and the presence of comorbidities. To determine the most reliable and valid predictors for a particular treatment, controlled trials that are randomized with larger samples will be required. This is due to the fact that it can be more difficult to detect interactions or moderators in trials that comprise only one episode per participant rather than multiple episodes over a long period of time.

Additionally, predicting a patient's response will likely require information on the severity of symptoms, comorbidities and the patient's own perception of the effectiveness and tolerability. Currently, only a few easily measurable sociodemographic variables as well as clinical variables are reliably related to response to MDD. These include age, gender and race/ethnicity, BMI, SES and the presence of alexithymia.

The application of pharmacogenetics in treatment for depression is in its infancy and there are many hurdles to overcome. First, it is important to be able to comprehend and understand the definition of the genetic factors that cause depression, as well as an understanding of a reliable indicator of the response to treatment. Ethics such as privacy and the ethical use of genetic information must also be considered. In the long term, pharmacogenetics may be a way to lessen the stigma associated with mental health treatment and to improve treatment outcomes ketamine for treatment resistant depression those struggling with depression. But, like all approaches to psychiatry, careful consideration and planning is essential. For now, it is best to offer patients a variety of medications for depression that are effective and encourage them to speak openly with their physicians.